ArticleRheumatology international2025
Anterior segment alterations in fibromyalgia syndrome: a cross-sectional study on dry eye disease, meibomian gland dysfunction, and astigmatism.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Risk of Incident Dry Eye Disease Among Patients With Chronic Pain Conditions.American journal of ophthalmology · 2026Article
- The Role of Behavioral and Psychological Interventions in Chronic Ocular Pain.Current pain and headache reports · 2026Review
- Major ozone therapy improves disease severity without affecting retinal microvascular parameters in fibromyalgia syndrome: an observational pre-post study.Rheumatology international · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia syndrome (FMS) is an ongoing disorder distinguished by its multifaceted characteristics. There has been increasing interest in its ophthalmologic aspects. This study evaluated the anterior segment parameters of the eye in patients with FMS, comparing them to healthy controls. Furthermore, correlations with disease activity were analyzed. This research was structured as a cross-sectional and comparative analysis. Data was collected at a tertiary care education and research hospital from August 20, 2024, to November 15, 2024. The participants' central corneal thickness, uncorrected and best-corrected visual acuities, refraction parameters, intraocular pressure, meibomian gland dysfunction (MGD), and dry eye disease (DED) parameters were evaluated. There were no significant differences in visual acuity, spherical equivalent, intraocular pressure, and central corneal thickness between FMS and healthy controls (p > 0.05). The median astigmatism in the right eye (diopter) was - 0.50 (-8.25-0) for the FMS group and - 0.12 (-1.75-0.50) for the control group (p = 0.012). The left eye data were - 0.50 (-2-1.50) for the FMS group and 0 (-1.75-0.75) for the control group (p = 0.056). MGD was identified in 26 (36.6%) individuals in the FMS group, whereas it was identified in 3 (4.3%) participants in the control group (p < 0.001). DED was detected in 43 (60.6%) participants in the FMS group and 15 (21.4%) participants in the control group (p < 0.001). FMS patients had higher rates of astigmatism, MGD, and DED compared to healthy controls, underscoring the necessity for routine anterior segment assessments. These data suggest possible ocular involvement in FMS, which warrants further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.